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Effects of guanidino and uremic compounds on nitric oxide pathways.
Aminoguanidine, N°-monomethyl-L-arginine (L.NMMA), N°N°di-
methyl-L-arginine (asymmetric dimethylarginine; ADMA), creatinine,
guanidinosuccinic acid, guanidinopropnonic acid and methylguanidine
were added to cultures of activated munne macrophages. Only ami-
noguanidine, ADMA, L-NMMA and methylguanidine inhibited nitrite
production in a dose-dependent manner. In the presence of 100 LM
arginine, nitrite production was inhibited by 31.8 7.1% by ADMA
(100 sM; P < 0.01) but the same dose of methylguanidine was without
effect. A higher dose of methylguanidine (1000 M) inhibited nitrite
production by 47.6 5.6% (P < 0.001). The effects of these compounds
were also tested on relaxation of human saphenous veins. L-NMMA
and ADMA inhibited endothelium-dependent relaxations (EC50 = 4.7
1.1 M and 17.9 4.9 LM, respectively); methylguanidine caused
endothelium-independent contractions and reversed the relaxations to
bradykinin and sodium nitroprusside (EC50 >100 /.LM); aminoguanidine
was without effect. The results of this study suggest that of the
guanidino compounds which accumulate in renal failure, only ADMA is
a potent inhibitor of nitric oxide (NO) synthesis. Methylguanidine is a
weak inhibitor of nitric oxide synthesis, whereas the closely related
compound aminoguanidine appears to inhibit selectively the inducible
isoform of nitric oxide synthase and has no effect on constitutive NO
synthase in human veins.
Nitric oxide (NO) is synthesized from L-arginine by a family
of enzymes known as NO synthases. In the vasculature, basal
synthesis of NO by a constitutive enzyme present in the
endothelium provides a continuous vasodilator influence that
regulates arterial tone and blood pressure in animals [1] and
humans [21. In the immune system, synthesis of NO by an
inducible isoform of NO synthase expressed in macrophages
and other leukocytes exposed to bacterial endotoxin or certain
cytokines is a mechanism of cytotoxicity towards pathogens
and tumor cells [3]. The synthesis of NO by constitutive or
inducible NO synthases can be inhibited by guanidino-substi-
tuted analogues of arginine, including N'-monomethyl-L-argi-
nine (L-NMMA), and these compounds have provided useful
tools with which to study the biology of NO in vitro and in vivo.
Inhibition of NO synthesis by L-NMMA causes hypertension
[1] and immune dysfunction [4] in experimental animals and
increases vascular resistance in healthy volunteers [2].
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Guanidino-substituted analogues of L-arginine that inhibit
NO synthesis also occur endogenously. One of these, N°N°-
dimethyl-L-arginine (asymmetric dimethylarginine; ADMA),
has been isolated from human urine and plasma [5] and is
released by human endothelial cells [6]. This finding raises the
possibility that endogenous inhibitors of NO synthase modify
the activity of the enzymes and contribute to the physiological
or pathophysiological regulation of the L-arginine:NO pathway.
Indeed, a possible pathophysiological role for endogenous NO
synthase inhibitors in renal failure has been suggested. Accu-
mulation of ADMA occurs in patients with end-stage chronic
renal failure [5] and inhibition of NO synthesis by this com-
pound might contribute to some of the vascular, immunological
or neurological features of this condition [5]. Other guanidino
compounds, including methylguanidine, guanidinosuccinic acid,
guanidinoproprionic acid and creatinine also accumulate in renal
failure and have been implicated as uremic toxins [7]. These
compounds are structurally related to certain NO synthase
inhibitors (Fig. 1); however, whether they also inhibit NO
synthesis or affect the tone of human blood vessels is not
known. In the present study we have examined the effects of
various endogenous and exogenous guanidino compounds on
endothelium-dependent relaxation of human saphenous vein
and nitrite production by the murine monocyte/macrophage cell
line J774 [8].
Methods
Organ bath studies
Specimens of saphenous vein were obtained from patients
without renal failure who were undergoing coronary bypass
surgery. Vessels were stored in cold Krebs solution of the
following composition (mM): NaCI 118, KC1 4.7, CaCI2 2.5,
KH2PO4 1.2, MgSO4 1.2, NaHCO3 25, and glucose 11, and used
within 24 hours. Each vein was freed of connective tissue and
cut into rings 3 to 5 mm long. Rings of saphenous vein were
suspended between two hooks connected to a transducer
(Statham UC3, Gould Inc., Cleveland, Ohio, USA) for the
measurement of isometric force. The preparations were sus-
pended in 10 ml organ baths filled with oxygenated (95% 02/5%
C02) warmed (37°C) Krebs solution in the presence of indo-
methacin (10 jsM). Basal tension was initially set at 4 g and the
rings were allowed to equilibrate until the resting tension was
stable at 2 g (1 to 3 hi-). This tension gave optimal contractile
responses in these vessels (our unpublished observations). The
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rings were washed every 20 minutes. Veins which generated an
active tone of less than 1 g in response to phenylephrine (10 M)
were discarded.
Endothelial integrity. To test the functional integrity of the
endothelium vessels were pre-contracted with phenylephrine
(0.9 ts; EC50) and those vessels which showed > 50% relax-
ation to bradykinin (0.5 M) were designated "endothelium-
intact." Other vessels were discarded. In some experiments the
endothelium was removed by rubbing the intimal surface with
the tip of a pair of forceps, and those vessels that showed <5%
relaxation to bradykinin were designated "endothelium-denud-
ed."
Effects of guanidino compounds on contraction. Dose-re-
sponse curves to L-NMMA (1 to 300 LM), ADMA (1 to 300
jsM), aminoguanidine (1 to 1000 sM) or methylguanidine (1 to
1000 /LM) were constructed in veins pre-contracted with phe-
nylephrine (0.9 oi; EC5Ø).
Effects of guanidino compounds on relaxation. Vessels were
pre-contracted with phenylephnne (0.9 pM; EC50) and relaxed
with either bradykinin (0.5 jiM) or an equi-effective concentra-
tion of sodium nitroprusside (0.02 to 0.04 jiM). Once the
relaxation had stabilized, dose-response curves were con-
structed to L-NMMA (1 to 300 jiM), ADMA (1 to 300 jiM),
aminoguanidine (1 to 1000 jiM) or methylguanidine (1 to 1000
jiM).
Nitrite production by J774 cells
J774 cells (American Tissue Culture Catalogue T1B 67, page
231) were grown as monolayers in a 1:1 mixture of medium 199
supplemented with Earle's modified salts and medium RPM!
1640 supplemented with 10% fetal calf serum and 2 mrs glu-
tamine. The arginine content of the media was varied from 100
to 3600 jiM.
J774 cells were stimulated with Salmonella typhosa lipopoly-
saccharide (10 jig/ml) for 18 hours. Cells were harvested by
scraping them from the flask and resuspended in fresh culture
medium at a concentration of approximately 3 million cells/mi.
Aliquots (250 d) of this suspension were plated in 24 well plates
(approximately 0.7 million cells per well). After two to three
hours when the cells had become adherent to the plates, the
medium was replaced with 250 jil of fresh medium containing
L-NMMA, ADMA, methylguanidine, aminoguanidine, guanidi-
nosuccinic acid, guanidinoproprionic acid or creatinine in con-
centrations ranging from 1 to 1000 jiM. In some experiments
dose-response curves to ADMA were also constructed in
glutamine-free medium. After 20 hours 100 jil of the superna-
tant was removed and nitrite concentration determined using a
modification of the method described by Green et al [9]. Briefly,
100 jil of Griess reagent (1% sulphanilamide, 0.1% napthylene
diamine, 2.5% H3P04) were mixed with 100 jil of culture
medium, and after a 10-minute incubation period at room
temperature absorbance was measured at 510 nm. Nitrite
concentration was determined by reference to a standard curve.
Drugs
The following drugs were used: aminoguanidine (Sigma
Chemical Co. Ltd, Poole, Dorset, UK), L-arginine hydrochlo-
ride (Sigma), bradykinin (Sigma), glutamine (Gibco Ltd, Paisley,
Scotland, UK), guanidinoproprionic acid (Sigma), guanidino-
succinic acid (Sigma), indomethacin (Sigma), methylguanidine
(Sigma), napthylene diamine (Sigma), N°.monomethyl-L-
arginine (Wellcome Research Laboratories, Beckenham, Kent,
UK), N°N°-dimethyl-L-arginine (Welicome), phenylephrine
(Sigma), sodium nitroprusside (Sigma) and sulphanilamide (Sig-
ma). For organ bath experiments the compounds were dis-
solved in distilled water on the day of each experiment.
Indomethacin (Sigma) was dissolved in 5% Na2CO3. Lipolysac-
charide (Salmonella typhosa) was obtained from Sigma. Cul-
ture medium was obtained from Gibco. Arginine-free media
was obtained from Integra Biosciences (Northumbria Biologi-
cal, Northumberland, UK). Tissue culture plastic was obtained
from Falcon (Marathon Laboratory Supplies, London, UK).
Calculations and statistics
The contractile effects of guanidino compounds are ex-
pressed as percentage of the phenylephrine pre-contraction.
The effects of guanidino compounds on bradykinin- or sodium
nitroprusside-induced relaxations are expressed as percentage
reversal of the relaxant response. Results are expressed as
mean standard error of the mean (sEM) and compared by
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Student's t-test for paired or unpaired observations as appro-
priate, where P < 0.05 is considered significant. EC50 values
were obtained from sigmoid logistic curves.
Results
The mean contraction to phenylephrine (10 ILM) in endothe-
hum-intact rings was 5.9 0.4 g and in endothelium-denuded
vessels was 3.8 0.6 g. Endothelium-intact rings pre-con-
tracted with phenylephrine (0.9 J.LM), relaxed by 84.1 11.6%
to bradykinin (P < 0.001); denuded rings relaxed by less than
1% (0.9 0.6%; NS).
Organ bath studies
Effect of guanidino compounds on contraction. L-NMMA
and ADMA produced small endothelium-dependent contrac-
tions of human saphenous veins submaximally contracted with
phenylephrine. In endothelium-intact vessels L-NMMA (300
LM) increased tone to 14.6 6.7% of that produced by
phenylephrine alone, but this increase in tone did not reach
statistical significance (N = 6; P > 0.1). ADMA (300 M)
produced similar increases in tone (21.9 4.9%) in endothelium-
intact vessels, which were statistically significant (N = 6; P <
0.05). Neither ADMA nor L-NMMA had any effect on the tone
of denuded vessels (N 4). Methylguanidine produced dose-
dependent, endothelium-independent contractions. In endothe-
hum-intact vessels, methylguanidine (1000 M) increased tone
to 49.5 13.1% of that produced by phenylephrine alone (P <
0.05; N 5). In endothelium-denuded vessels, methylguanidine
(1000 M) increased tone to 24.2 3.7% (N = 4;P < 0.05). The
increase in tone produced by methylguanidine did not differ
between endothelium-intact and endothelium-denuded vessels
(F> 0.2). Aminoguanidine (1000 jsM) had no effect on venous
tone (N = 3).
Effect of guanidino compounds on relaxation. L-NMMA,
ADMA and methylguanidine caused dose-dependent reversal
of bradykinin-induced relaxation (Fig. 2). The EC50 for
L-NMMA was 4.7 1.1 M (N = 4), for ADMA was 17.9 4.9
M (N = 4), and for methylguanidine was >100 M (N 5).
The concentration of ADMA found in the plasma of certain
patients with end-stage chronic renal failure (up to 5 pM) caused
a 19.5 10.8% reversal of the relaxation to bradykinin (N =4).
Methylguanidine caused dose-dependent reversal of the relax-
ation produced by sodium nitroprusside (Fig. 3; N = 5),
whereas L-NMMA and ADMA were without significant effect.
Aminoguanidine had no effect on the relaxation produced by
bradykinin or sodium nitroprusside (N = 5).
Nitrite production by J774 cells
L-NMMA, ADMA and aminoguanidine produced dose-
dependent inhibition of nitrite production by J774 cells (Fig. 4).
L-NMMA and aminoguanidine were more potent than ADMA
although all three compounds produced the same maximal
inhibition. The potency of the inhibitors diminished as the
arginine concentration of the culture medium increased (Fig. 5).
In the presence of 100 .tM arginine in the culture medium, nitrite
production was inhibited by 66.6 3.0% by 100 jiM L-NMMA
(P < 0.0001), 76.2 2.7% by 100 jiM aminoguanidine (P <
0.0001) and 31.8 7.1% by 100 jiM ADMA (P < 0.01).
Reduction of the glutamine content of the medium from 2 mM to
0 caused a small decrease in the potency of ADMA such that
Guanidine concentration, M
Fig. 2. Effect of guanidino compounds on endothelium-dependent re-
laxation of human saphenous vein. Vessels were precontracted with
phenylephrine (0.9 sM) and relaxed with bradykinin (0.5 /LM). Results
are expressed as percentage reversal of the relaxation to bradykinin.
Symbols are: L-NMMA (V; N 4), ADMA (0; N = 4), methylguani-
dine (A; N = 5), and aminoguanidine (0; N = 5).
the EC50 increased by approximately twofold (N = 10; P <
0.05). Methylguanidine produced inhibition of nitrite produc-
tion only at high concentrations and in the presence of low
arginine concentrations; in the presence of 100 jiM arginine,
1000 jiM methylguanidine produced 47.6 5.6% inhibition of
nitrite synthesis (N = 6; P < 0.001). The effect of arginine on
the potency of methylguanidine suggests that its inhibitory
action is due to its effect on NO synthase and is not related to
cell viability. Guanidinoproprionic acid, guanidinosuccinic acid
and creatinine had no effect on nitrite production (N = 4 for
each; data not shown).
Discussion
The results of this study show that the endogenous guanidino
compound ADMA inhibits NO synthesis and endothehium-
dependent relaxation of human blood vessels at concentrations
of a similar order to those reported to occur in the plasma of
certain patients with chronic renal failure. However, the puta-
tive uremic toxins methylguanidine, guanidinosuccinic acid,
guanidinoproprionic acid and creatinine have little effect.
ADMA and L-NMMA produced dose-dependent inhibition
of nitrite production by macrophages (J774 cells) and fully
reversed the relaxation to bradykinin in human saphenous
veins. The effects of ADMA on nitrite production are consistent
with earlier observations demonstrating that this arginine ana-
logue inhibits the cytotoxic effect of activated macrophages and
is slightly less potent than L-NMMA in this system [10]. There
was a large increase in the potency of ADMA when the
extracellular concentration of arginine was low and a small
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Fig. 3. Effect of methylguanidine on endotheliu,n-dependent and en-
dothelium-independent relaxation. Vessels were precontracted with
phenylephrine (0.9 M) and relaxed with either bradykinin (; 0.5 LM;N = 5) or sodium nitroprusside (A; 0.02 to 0.04 LM; N = 5). Results are
expressed as percentage reversal of the relaxation to bradykinin or
sodium nitroprusside.
decrease following incubation in glutamine-free medium, an
effect which may be due to enhanced intracellular arginine
synthesis under these conditions [11].
The detailed effects of ADMA on human isolated vessels or
venous reactivity have not been studied previously. ADMA
produced small endothelium-dependent contractions of rings of
human saphenous vein, confirming previous reports showing
that human veins release little NO under resting conditions [12].
In addition, ADMA fully reversed the relaxation to bradykinin.
Similar effects were seen with L-NMMA, a widely used inhib-
itor of NO synthesis that also occurs endogenously but in
concentrations at least 10-fold lower than those of ADMA [5].
The finding that L-NMMA and ADMA fully reversed the
relaxant response to bradykinin contrasts with earlier studies
showing that L-NMMA produced only about 40% inhibition of
bradykinin-induced relaxation of human veins in vitro [13]. The
reason for the more complete reversal seen in the present study
relates to the experimental design. When NO synthase inhibi-
tors are added after relaxation has occurred the inhibitory effect
is greater than when they are added prior to relaxation [14].
This might indicate that these compounds have greater access
to the enzyme once it is activated, that transport of the inhibitor
is increased after the cells are stimulated with agonist, or that
the initial relaxation to bradykinin is mediated by a preformed
stable adduct of NO and the relaxation is sustained by newly
synthesized NO [14]. Whatever the mechanism, the experimen-
tal protocol used in this study should maximize the chance of
detecting an effect of a putative NO synthase inhibitor on
vascular relaxation.
ADMA is not the only guanidino compound that circulates in
Guanidine concentration, M
Fig. 4. Inhibition of J774 macrophage nitrite production by guanidino
compounds. Cells were stimulated with lipopolysaccharide for 18 hours
and then incubated with each compound in the presence of 100 M
arginine for 20 hours. Symbols are: L-NMMA (V; N = 6), ADMA (0;N = 6), methylguanidine (A; N = 6), and aminoguanidine (0; N = 6).
increased concentration in patients with renal failure and may
inhibit NO synthesis. Methylguanidine, guanidinosuccinic acid,
guanidoproprionic acid and creatinine have been postulated as
uremic toxins [7] or potential inhibitors of NO synthase [15],
but only methylguanidine (at concentrations of 1000 M) inhib-
ited nitrite synthesis by J774 cells. The finding that guanidino-
succinic acid, guanidinoproprionic acid and creatinine did not
inhibit NO synthesis is not unexpected since these compounds
do not have modifications to the guanidino group which seem to
be necessary for potent inhibition of the enzyme [16], whereas
methylguanidine is identical to the guanidino end of L-NMMA
and is structurally similar to aminoguanidine, a compound
reported to inhibit selectively the inducible isoform of NO
synthase [17]. This study confirms that methylguanidine (1000
M) is an inhibitor of NO synthesis [17], but is ineffective at the
concentrations found in the circulation of patients with renal
failure (0 to S M) [7].
Lower concentrations of methylguanidine (100 M) reversed
endothelium-dependent relaxation to bradykinin. However,
they also produced endothelium-independent contractions and
reversed the relaxations to sodium nitroprusside. These find-
ings contrast with those in animal tissues in which methylguani-
dine has been shown to produce endothelium-dependent relax-
ation [18]. The apparent reversal of bradykinin relaxation in the
present study is most likely a consequence of functional antag-
onism resulting from the increased starting tension in rings
pre-contracted with phenylephrine and methylguanidine rather
than inhibition of NO synthesis. The endothelium-independent
mechanisms by which methylguanidine might alter vascular
tone include inhibition of sodium-potassium ATPase [19], stim-
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ulation of release of cathecholamines from nerve terminals [201,
inhibition of monoamine oxidase [211 or inhibition of diamine
oxidase [22]. It seems unlikely that inhibition of NO synthase
fully explains the pressor effect of high concentrations of
methylguanidine seen in some [23, 17] but not all [24] experi-
ments in animals.
Interestingly, the structurally-related compound aminoguani-
dine caused potent dose-dependent inhibition of nitrite synthe-
sis by J774 cells (EC5Ø = 26.2 4.3 at 100 M L-arginine)
but had no effect on venous tone or the relaxation to bradykinin
even at concentrations in excess of 1000 /SM. Similar to the
effects of L-NMMA and ADMA, the inhibitory effects of
aminoguanidine were most marked in the presence of culture
medium containing a reduced amount of L-arginine. These
findings are consistent with the suggestion that aminoguanidine
is a selective inhibitor of inducible NO synthase and demon-
strate for the first time that this compound has virtually no
effect on the tone or responses of healthy human blood vessels.
ADMA, methylguanidine, guanidinosuccinic acid, creatinine
and guanidinoproprionic acid are naturally occurring guanidino
compounds that accumulate in renal failure. Despite structural
similarities between these compounds and known inhibitors of
the L-arginine:NO pathway, only ADMA and methylguanidine
inhibit NO synthesis. In the concentrations found in the plasma
or urine of certain patients with renal failure, or those that may
occur locally within cells [6], it is possible that ADMA, but not
methylguanidine would inhibit NO synthesis. This effect would
be most marked when local levels of arginine are reduced.
Inhibition of NO synthesis produces widespread effects in-
cluding hypertension [I], immune dysfunction [4] and neurolog-
ical changes [25], and prolonged inhibition of NO synthesis with
guanidino-substituted arginine analogues also produces renal
damage [26]. ADMA fulfills certain criteria for a uremic toxin
and has a clear mechanism of action to alter physiological
processes. However, other studies have implicated increased
rather than decreased NO production in platelets in the patho-
genesis of the bleeding tendency of uremia [27, 28]. The reasons
for these apparently contradictory findings are not yet clear,
and further studies will be needed to determine the precise
contribution of ADMA (either local or systemic) and the
L-arginine:nitric oxide pathway in different cell types in the
pathogenesis of renal failure.
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